LGND - Company ID 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $174.93M | $72.31M | $22.95M | $45.01M | $19.52M | $47.62M |
| Short-term investments | $558.59M | $183.86M | $147.35M | $166.86M | $321.59M | $363.57M |
| Receivables | $59.60M | $38.38M | $32.92M | $30.42M | $85.45M | $56.85M |
| Inventory | $9.13M | $14.11M | $23.97M | $13.29M | $27.33M | $26.49M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $832.27M |
| $331.56M |
| $237.43M |
| $263.60M |
| $464.75M |
| $500.56M |
| Property, plant & equipment | $3.57M | $15.13M | $15.61M | $12.48M | $20.51M | $14.43M |
| Goodwill | $101.54M | $105.25M | $103.37M | $105.67M | $181.21M | $189.66M |
| Total assets | $1.56B | $941.77M | $787.22M | $762.67M | $1.30B | $1.36B |
| Accounts payable | $3.24M | $5.23M | $2.43M | $5.31M | $8.40M | $3.78M |
| Total current liabilities | $37.45M | $37.11M | $16.78M | $98.81M | $41.66M | $100.11M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $543.42M | $111.33M | $86.30M | $165.18M | $476.43M | $652.76M |
| Retained earnings | $608.09M | $498.98M | $503.02M | $450.86M | $449.09M | $391.95M |
| Total equity | $1.02B | $830.44M | $700.91M | $597.49M | $821.16M | $709.52M |